ARS Pharmaceuticals, Inc.

NASDAQ:SPRY

Biotechnology

Healthcare
$3.69 -3.51%

-$0.35 today

Market cap
$370.95M
Beta
0.83
P/E (TTM)
-4.8
EPS (TTM)
-$1.99
52W Low $6.66High $18.90

Volume 1.70M

Average 1.67M

SPRY Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

ARS Pharmaceuticals, Inc.NASDAQ: SPRY

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue growth accelerates

Q1 FY2026 revenue of $22.68M rose 184.5% year over year, ahead of the +1.9% change in trailing-twelve-month revenue. Sequentially, it fell 19.2% from the prior quarter. Over 3 fiscal years it compounded at +300.1% a year.

Context

  • Revenue increased in 1 of the last 3 fiscal years.

What to watch

Whether revenue reaches the consensus estimate from 3 analysts of $120.44M (+42.9%) for the fiscal year ending Dec 2026, a step up from the -5.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$22.68M-19.2% QoQ
Last fiscal yearDec 2025
$84.28M-5.5% YoY
LTMMar 2026
$98.99M+1.9% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+184.5%+99.3%-85.2 pp
1 year-5.5%+42.9%+48.4 pp
3-year CAGR+300.1%+42.8%-257.2 pp
5-year CAGR+33.2%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
84.28M USD
Year-over-year change
-5.5%
4-year CAGR
+97.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How SPRY compares with its peers on the latest reported figures

  • SPRY's LTM Mar 2026 revenue of $98.99M is the 3rd highest of the 4 companies compared; the peer median is $314.85M.
  • Its year-over-year change of +1.9% is the 3rd highest of 4, against a peer median of +21.2%.
  • Over three fiscal years its annual growth of +300.1% compares with a peer median of +38.3%.
SPRY Competitors Peer median
Revenue for SPRY and competitors
Company Period LTM YoY 3-year CAGR
MNKDMannKind CorporationLTM Mar 2026$360.78M +21.2%+51.8%
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$314.85M +41.5%+38.3%
SPRYARS Pharmaceuticals, Inc.LTM Mar 2026$98.99M +1.9%+300.1%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$50.27M -7.3%-2.2%
Peer median (excluding SPRY) $314.85M+21.2%+38.3%

Competitors are the stored peer set for SPRY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue5.51M1.32M30K89.15M84.28M
Cost of Revenue213K17.12M020.56M20.42M
Gross Profit5.29M(15.8M)30K68.59M63.86M
Gross Margin96.1%-1200.9%100.0%76.9%75.8%
Research & Development20.27M18.38M20.27M19.58M13.18M
Selling, General & Admin4.69M18.66M47.28M0230.12M
Operating Expenses24.75M19.71M67.55M71.68M243.3M
Depreciation & Amortization213K319K73K79K1.37M
EBITDA(19.92M)(34.36M)(54.29M)8.37M(167.41M)
EBITDA Margin-361.9%-2611.2%-180973.3%9.4%-198.6%
Operating Income(19.45M)(35.52M)(67.52M)(3.08M)(179.45M)
Operating Margin-353.3%-2698.8%-225066.7%-3.5%-212.9%
Interest Income800K00010.67M
Interest Expense106K0002.6M
Other Income / Expenses(789K)834K13.16M11.37M8.07M
Income Before Tax(20.24M)(34.68M)(54.37M)8.29M(171.38M)
Pre-Tax Margin-367.7%-2635.4%-181216.7%9.3%-203.3%
Income Tax Expense000288K(80K)
Net Income(20.24M)(34.68M)(54.37M)8M(171.3M)
Net Margin-367.7%-2635.4%-181216.7%9.0%-203.3%
EPS (Basic)(0.70)(0.87)(0.57)0.08(1.74)
EPS (Diluted)(0.70)(0.87)(0.57)0.08(1.74)
Weighted Avg Shares28.87M39.96M95.22M96.94M98.57M
Weighted Avg Shares (Diluted)28.87M39.96M95.22M102.39M98.57M

ARS Pharmaceuticals, Inc.

NASDAQ:SPRY

Intrinsic Alpha fair value

Locked

Current Price

$3.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.